Our societal impact
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
We seek to provide solutions for some of the world’s most pressing global public health challenges and work collectively—within our walls and externally with partners—to advance better health for all.
At Johnson & Johnson, our environmental, social and governance (ESG) strategy is designed to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere.
At Johnson & Johnson, our environmental, social and governance (ESG) strategy is designed to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere.
How we create economic, environmental and social value for all those we serve
ESG and sustainability resources
Our Race to Health Equity
For nearly 20 years, both in our laboratories and on the ground in countries impacted by TB and MDR-TB, Johnson & Johnson has been supporting global efforts to end TB and combat AMR.
More from Johnson & Johnson
What to know about We All Belong: 2023 DEI Impact Review
The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.
Giving the gift of sight
In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.
Inside the development of a revolutionary treatment for blood cancers
In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.